65,437 trials
Allergic Rhinitis
Primary: Comparison of Systemic Exposure Measured by AUC, ng*hr/L, (Area Under the Serum Concentration) of Des-ciclesonide With Ciclesonide Nasal Spray, and Ciclesonide HFA Nasal…
Cervical Cancer · Uterine Cancer · Vaginal Cancer
Primary: Mean Doses Given — 93.9; 63.2; 58.63 Gy
Muscle Atrophy · ACL Reconstruction · Trauma
Primary: Changes in Lean Mass — 2.8; -0.1; 2.16; 0.01 kg — p=0.35
Neutropenia · Breast Cancer
Primary: Duration of Severe Neutropenia (DSN) in Cycle 1 — 0.20; 0.35 days — p=<0.0001
Pain · Opiates · Alcohol Drinking
Primary: Rates of Risky Drinking, Week 13 — 3.03; 2.46 risky drinking weeks
Coronavirus Disease 2019
Primary: Number of Participants With at Least 1 Serious Adverse Event — 3; 6 Participants
Crohn's Disease
Primary: Percentage of Participants Achieving Endoscopic Response at Week 12 — 10.9; 25.8; 37.5; 43.8 percentage of participants — p=0.079
Prone Positioning · High Flow Nasal Cannula · Acute Respiratory Distress Syndrome
Primary: Treatment Failure (Intubation or Death) — 45; 45 Participants
Human Papilloma Virus · Cervical Cancer · Oropharyngeal Cancer
Primary: Percentage of Participants That Achieved an Objective Confirmed Complete or Partial Overall Tumor Response — 31; 7.7 percentage of participants
Anterior Cruciate Ligament Tear
Primary: Knee Flexion — -0.05; 0.01 Degrees
Pharmacogenetic Testing
Primary: Clinical Global Impression — 4.07; 3.96 units on a scale — p=<0.05
Urinary Tract Infections
Primary: Number of Patients With Adverse Events During and After FMT — 1 Participants
Ulcerative Colitis
Primary: Percentage of Participants With Clinical Remission at Week 12 — 13.3; 24.2 percentage of participants — p=0.00006
Advanced Cancer
Primary: The Number of Participants Experiencing Adverse Events (AE) — 11 Participants
Breast Cancer · Bone Metastases
Primary: Objective Response in Bone From Time of Initiation of Therapy to > 6 Months — 8; 7 Participants